Bingna Guo has extensive experience in international anti-corruption investigation and compliance matters, cross-border litigation, international commercial arbitration and mediation, regulatory matters, crisis management, and complex commercial litigation. Bingna represents companies and individuals in internal investigations and enforcement actions, including FCPA/anti-corruption related investigations, fraud, embezzlement, conflicts of interest investigations, compliance risk assessment, and pre-transaction compliance diligence. She also advises companies on comprehensive compliance programs and trainings.
Bingna has litigated cases in various legal jurisdictions, and provides clients with strategic and case management advice for parallel proceedings involving multiple jurisdictions. She formerly worked in the litigation department of a leading Chinese law firm under secondment, where she litigated cases before Chinese courts. Bingna has extensive relationships with leading local counsel, and is able to effectively coordinate local litigation and counsel on litigation and dispute resolution proceedings in China.
Prior to joining White & Case, Bingna was a partner of another leading US law firm.
Bingna has been recognised by Chambers & Partners 2018 in Corporate Investigations/Anti-Corruption – China. She was also named in the 2014 ALB China Client Choice Top 20 and recommended for having "deep insights, outstanding skills, extensive experience and responsiveness."
Bingna was named a Hauser Global Scholar for 2001-2002 at New York University School of Law, selected by an international committee chaired by the President of the International Court of Justice. She is a member of the New York bar, and also passed the Chinese bar examination in 1999.
Advised a leading multinational medical device company in an internal investigation project with respect to FCPA and Chinese anti-corruption law issues; advised the company on the Chinese court case as a result of Chinese judicial authorities' actions.*
Conducted various internal investigations for a multinational healthcare company with respect to FCPA and Chinese anti-corruption law issues.*
Represented a leading US retail company in an FCPA investigation regarding government relations activities and a corporate internal investigation with respect to management self-dealings in response to whistleblower allegations.*
Advised a leading financial institution in an internal investigation regarding allegations of bribery with respect to investment opportunities.*
Conducted pre-transaction diligence for a leading international medical device company involving businesses in multiple jurisdictions, and advised the company on pre-closing and post-closing actions in connection with FCPA and Chinese anti-corruption laws.*
Conducted pre-transaction diligence and advised a leading private equity firm on FCPA and Chinese anti-corruption law risks in connection with various portfolio investments in China.*
Conducted compliance review of a leading pharmaceutical company, and advised the company on compliance controls and remedial actions.*
Developed a comprehensive compliance program for the world's largest solar energy company and provided continuing advice on specific compliance issues in China.*
Represented the audit committee of a US listed China-based company in an internal investigation with respect to FCPA and Chinese anti-corruption law issues arising out of whistleblower allegations.*
Advised a world leading semiconductor company on compliance programs and procedures, and conducted compliance health check and compliance trainings for the company.*
Represented the Special Committee of the Board of Directors of an international newspaper company in a comprehensive internal investigation regarding breach of fiduciary duty and fraud claims.*
* Experience prior to joining White & Case
"Why You Need to Know about Revised Legislation on Commercial Bribery, the Newly Established National Supervision Commission, and New Policies on Drug and Medical Device Approval and Innovation," 12th Advanced Forum on FCPA & Anti-Corruption for the Life Sciences Industry by American Conference Institute, New York (June 2018)
"ISO 37001: Industry Perspectives on When and How to Incorporate into your Compliance Initiatives," 11th China Forum on Anti-Corruption by American Conference Institute, Shanghai (June 2018)
"China Anti-Corruption 2.0: How New Legislation on Commercial Bribery Elevates Risks for MNs and Increases Standard for Compliance Controls - Special Focus on Third Party Risks and Pitfalls with the Media," 11th Advanced Forum on FCPA & Anti-Corruption for the Life Sciences Industry by American Conference Institute, New York (June 2017)
"Mock Government Investigation: A Complete Guide on How to Respond to the More Frequent Investigations by Chinese Government Agencies, AIC, Police, Prosecutor, and Court," 10th China Summit on Anti-Corruption by American Conference Institute, Shanghai (June 2017)
"How to Resolve Complex Issues on Privilege, State Secret, Data Privacy for Cross Border Investigations," 9th China Summit on Anti-Corruption by American Conference Institute, Shanghai (June 2016)
"Balancing FCPA Compliance with European and Asian Data Privacy Restrictions," 17th Annual New York Conference on the Foreign Corrupt Practices Act by American Conference Institute, New York (May 2015)
Co-Chair, "Third Party Risk Management in China" Seminar by American Conference Institute, Shanghai (January 2015)
"Intersection of the FCPA and Chinese Anti-bribery Laws," Global Anti-Corruption Regulatory and Enforcement Update by American Conference Institute, Washington DC, (July 2014)
"Status Update on China's New Anti-Bribery Orientation and Enforcement Activity under the Current Leadership," 7th China Summit on Anti-Corruption by American Conference Institute, Shanghai (June 2014)
"US Litigation Explained: the Process, the Potential Pitfalls, and the Path to Victory," US-China Legal Summit, Hong Kong, (March 2014)
Co-author, "China's Legal System Came A long Way in Enforcing Creditor Claims against Bad Debt," South China Morning Post (July 2017)
Co-author, "China's Draft Cyber Law Raises Concerns for Foreign Businesses," Financial Times (November 2015)
Co-author, "Anti-corruption Tips for Health Care Cos. Operating in China," Law360 (September 2015)
Co-author, "Handling Foreign Investment Disputes," China Law & Practice (March 2011)
Corporate Investigation/Anti-corruption practice, recognized by Chambers Asia 2018, China
Named to the ALB China Client Choice Top 20, Asian Legal Business, 2014